Literature DB >> 6994509

Parathyroid hormone metabolism and its potential as a uremic toxin.

E Slatopolsky, K Martin, K Hruska.   

Abstract

Secondary hyperparathyroidism is a universal complication of chronic renal failure. It has been proposed that the markedly elevated levels of immunoreactive parathyroid hormone (i-PTH) in uremia may represent a "uremic toxin" responsible for many of the abnormalities of the uremic state. Plasma i-PTH consists of a mixture of intact hormone, a single-chain polypeptide of 84 amino acids, and smaller molecular weight hormonal fragments from both the carboxy- and amino-terminal portion of the PTH molecule. The hormonal fragments arise from metabolism of intact PTH by peripheral organs as well as from secretion of fragments from the parathyroid glands. The structural requirements for the known biological actions of PTH reside in the amino-terminal portion of the PTH molecule. Carboxy-terminal fragments, biologically inactive at least in terms of adenylate cyclase activation, hypercalcemia, or phosphaturia, depend on the kidney for their removal from plasma, and thus accumulate in the circulation in chronic renal failure. It is unknown at the present time if other biological effects of these carboxy-terminal fragments may contribute to some of the biochemical alterations observed in uremia. The most significant consequence of increased PTH levels in uremia is the development of bone disease characterized by osteitis fibrosa. In addition, it would appear that PTH plays an important role in some of the abnormal electroencephalographic patterns observed in uremia. This may be due to a potential role of PTH in increasing calcium content of brain. Parathyroid hormone also has been implicated as a pathogenetic factor in many other alterations present in uremia, i.e., peripheral neuropathy, carbohydrate intolerance, hyperlipidemia, and other alterations. Unfortunately, outstanding clinical research is lacking in this field and conclusive experimental data are practically nonexistent. Further studies are necessary if one is to accept the concept of PTH being a significant "uremic toxin."

Entities:  

Mesh:

Substances:

Year:  1980        PMID: 6994509     DOI: 10.1152/ajprenal.1980.239.1.F1

Source DB:  PubMed          Journal:  Am J Physiol        ISSN: 0002-9513


  10 in total

1.  A prospective randomized pilot study on intermittent post-dialysis dosing of cinacalcet.

Authors:  Naveed Haq; Ahmed Chaaban; Nicole Gebran; Imran Khan; Fayez Abbachi; Muhyeddin Hassan; Roos Bernsen; Samra Abouchacra
Journal:  Int Urol Nephrol       Date:  2013-03-26       Impact factor: 2.370

Review 2.  Recent advances in the pathogenesis and nutritional treatment of chronic uremia.

Authors:  P Fürst; A Alvestrand; J Bergström
Journal:  Z Ernahrungswiss       Date:  1982-09

Review 3.  The membrane perspective of uraemic toxins: which ones should, or can, be removed?

Authors:  Sudhir K Bowry; Peter Kotanko; Rainer Himmele; Xia Tao; Michael Anger
Journal:  Clin Kidney J       Date:  2021-12-27

4.  White Matter Microstructure Changes and Cognitive Impairment in the Progression of Chronic Kidney Disease.

Authors:  Mengchen Liu; Yunfan Wu; Xixin Wu; Xiaofen Ma; Yi Yin; Huamei Fang; Sihua Huang; Huanhuan Su; Guihua Jiang
Journal:  Front Neurosci       Date:  2020-09-29       Impact factor: 4.677

Review 5.  Bone kidney interactions.

Authors:  Thomas L Nickolas; Sophie A Jamal
Journal:  Rev Endocr Metab Disord       Date:  2015-06       Impact factor: 6.514

6.  Transport of myo-inositol into endoneurial preparations of sciatic nerve from normal and streptozotocin-diabetic rats.

Authors:  K R Gillon; J N Hawthorne
Journal:  Biochem J       Date:  1983-03-15       Impact factor: 3.857

7.  Suppression of secondary hyperparathyroidism in children with chronic renal failure by high dose phosphate binders: calcium carbonate versus aluminium hydroxide.

Authors:  R H Mak; C Turner; T Thompson; H Powell; G B Haycock; C Chantler
Journal:  Br Med J (Clin Res Ed)       Date:  1985-09-07

Review 8.  The management of diabetic neuropathy in CKD.

Authors:  Rodica Pop-Busui; Laurel Roberts; Subramaniam Pennathur; Mathias Kretzler; Frank C Brosius; Eva L Feldman
Journal:  Am J Kidney Dis       Date:  2009-12-30       Impact factor: 8.860

9.  Effects of parathyroid hormone on skeletal muscle protein and amino acid metabolism in the rat.

Authors:  A J Garber
Journal:  J Clin Invest       Date:  1983-06       Impact factor: 14.808

10.  Effects of hemodiafiltration and high flux hemodialysis on nerve excitability in end-stage kidney disease.

Authors:  Ria Arnold; Bruce A Pussell; Timothy J Pianta; Virginija Grinius; Cindy S-Y Lin; Matthew C Kiernan; James Howells; Meg J Jardine; Arun V Krishnan
Journal:  PLoS One       Date:  2013-03-11       Impact factor: 3.240

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.